Survodutide SUR10 10MG

Survodutide SUR10 10MG  is a dual glucagon/GLP-1 receptor agonist develop by Boehringer Ingelheim and Zealand Pharma. The SUR10 10mg designation refers to the 10-milligram dose strength in the Survodutide clinical program.

Survodutide SUR10 10MG / Survodutide – Pipeline Online Shop

In 2016, more than 1.9 billion adults lived with overweight — defined as a body mass index (BMI) of 25. Moreover  over 650 million were living with obesity — defined as a BMI of 30, or more than one billion people around the world are living with obesity today. Moreover (1 in 8 of us) – and by 2030, that number could be more than double what it was in 2010. However overweight and obesity are complex chronic conditions involving abnormal. Another thing  excessive fat accumulation that present a risk to a person’s overall health.⁶

About metabolic dysfunction-associated steatohepatitis (MASH) 

MASH is a chronic and progressive liver disease caused by a build-up of fat in the liver. And is a moreover severe form of metabolic dysfunction-associate steatotic liver disease (MASLD).  In the U.S. cases of MASH are predict to rise by 63% between 2015 and 2030, from 16.5 million to 27.0 million cases. However MASH is a disease closely associate with interconnected cardiovascular, renal and metabolic conditions. Moreover it is also estimated that 34% of people living with obesity also have MASH.

Purchase Survodutide 10MG Online / Survodutide – Boehringer Ingelheim 

About survodutide (BI 456906) 

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. Survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardiovascular, renal and metabolic disease areas.

Essential Survodutides Peptide For Sale / Order Survodutide Near Me

About the SYNCHRONIZE-1 trial (NCT06066515)

About the SYNCHRONIZE Program  

These Survodutide is also being evaluated in three other global phase III studies for people living with overweight or obesity among key sub-populations.

.SYNCHRONIZE-2 enrolled adults with type 2 diabetes in a subset of the population.

.SYNCHRONIZE-MASLD enrolled a sub-population of adults with a confirmed or presumed diagnosis of MASH.

. SYNCHRONIZE-CVOT enrolled adults with cardiovascular disease, chronic kidney disease, or cardiovascular disease risk factors.

SYNCHRONIZE-JP in Japan and SYNCHRONIZE-CN in China are exploring survodutide for sub-populations of people living with obesity. SYNCHRONIZE-JP explores the relative change in liver fat, and also body composition parameters from baseline to Week 76 when treated with survodutide versus placebo, as a secondary endpoint.

About LIVERAGE and LIVERAGE-Cirrhosis

LIVERAGE and LIVERAGE-Cirrhosis are global Phase III clinical trials investigating. However  the efficacy and safety of survodutide in adults with MASH and fibrosis stages 2 or 3 and in those with compensated mash cirrhosis (fibrosis stage 4) respectively.

LIVERAGE will enroll approximately 1,800 adults, and LIVERAGE-Cirrhosis will enroll approximately 1,590 adults. In each trial, participants are randomized to receive weekly injections of either survodutide, reaching a maximum dose of 6 mg, or placebo.

SUR10 Survodutide Quality For Sale / Survodutide 10MG SUR10 USA FACTORY

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development. The company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow.

Boehringer Ingelheim’s Intended Audiences Notice 

This press release is issue from our Corporate Headquarters in Ingelheim. Germany  intend to provide information about our global business. Please be aware that information relates to help approve it’s status and labels of approve products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

^*The efficacy estimand is the estimated treatment effect assuming patients remained on treatment for the entire study duration. P-values for efficacy estimand are nominal

^†The treatment-regimen estimand is the estimated treatment effect, regardless of whether the patient adheres to the treatment, discontinues, or initiates other therapies

¹ Boehringer Ingelheim. Topline Results From A Study to Test Efficacy of Survodutide (BI456906) in Adults With Overweight or Obesity, Without Type

2 Diabetes. Data on file.

² Ness-Abramof R, Apovian CM. Nutr Clin Pract. 2008 Aug-Sep;23(4):397-404. 

³ Hanlon C, et al. Cli

n Liver Dis (Hoboken). 2022;19(3):106-110.

⁴ Zimmerman T, et al. Mol Metab 2022;66:101633.

⁵ World Obesity Federation. World Obesity Atlas 2025. Last accessed February 2026.

⁶ Bray A, et al. Obes Rev 2017;18:715-723. 

7 Handelsman Y, et al. Metabolism 2024;159:155931.

⁸ Ndumele C, et al. Circulation 2023;148:1606–1635.

⁹ Quek J, et al. Lancet Gastroenterol Hepatol 2023;8(1):20–30.

¹⁰ Shah M, Vella A. Rev Endocr Metab Disord 2014;15:181–187.

¹¹ Sanyal AJ, et al. N Engl J Med 2024;391:311–319.

¹² Arun A, et al. Cariology in Review 2025; 

¹³ Novikoff A. Peptides 2023; 165